In another encouraging vaccine development from the Old Continent, European Commission President Ursula von der Leyen announced on Saturday that the EU has struck a deal with BioNTech/Pfizer for up to 1.8 billion extra doses of their Covid-19 vaccine.
“Happy to announce that the EU Commission has just approved a contract for guaranteed 900 million doses (+900 million options) with BioNTech/Pfizer for 2021-2023," European Commission Chief tweeted from an EU summit in Portugal.
von der Leyen has previously said, “the mRNA technology used by BioNTech/Pfizer and other vaccine-makers has proven safe and effective.”
On Thursday, the EU Chief said that “we're vaccinating 30 Europeans every second.”
After a low start to the vaccination campaign, the 27-nation bloc is on track to have 70% of the adult population fully vaccinated by the end of July.
The euro is likely to receive a shot in the arm from the positive vaccine news, which could aid EUR/USD break through the 1.2200 barrier.
The main currency pair rallied hard to hit fresh ten-month highs of 1.2172 on Friday after the US NFP figures disappointed markets by a big margin and smashed the greenback across the board.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.